Multicenter, Open-label Trial, Evaluating the Efficacy and Safety of Perampanel Added to Monotherapy in Patients With Partial Onset Seizures With or Without Secondary Generalized Seizures
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 25 Aug 2017
At a glance
- Drugs Perampanel (Primary)
- Indications Epilepsy; Generalised seizures; Partial epilepsies
- Focus Therapeutic Use
- Sponsors Eisai Korea
- 21 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 24 May 2017 Planned End Date changed from 1 Jan 2018 to 1 May 2018.
- 24 May 2017 Planned primary completion date changed from 1 Jan 2018 to 1 May 2018.